Side-by-side · Research reference

PNC-27vsVIP

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-StrongHUMAN-REVIEWED18/41 cited

BPhase 3HUMAN-REVIEWED9/42 cited

PNC-27

p53-HDM-2 Peptide · Membrane-Targeting

32 AAPeptide lengthSarafraz-Yazdi 2022

12-26p53 domain

Pre-clinicalDevelopment stage

In vitro / Pre-clinical only

VIP

Neuropeptide · VPAC1/VPAC2 Agonist · Emergency Use Authorization (COVID-19 ARDS)

IntravenousPrimary routeBrown 2023

ARDSLead indicationUdupa 2025

Phase 3Development stage

IV infusion · Inhaled (investigational)Brown 2023 Boesing 2022

01Mechanism of Action

Parameter

PNC-27

VIP

Primary target

Membrane-bound HDM-2 protein on cancer cell surfaceSarafraz-Yazdi 2022 Krzesaj 2024

VPAC1 and VPAC2 G-protein-coupled receptorsUdupa 2025

Pathway

PNC-27 binds to membrane HDM-2 1-109 domain → transmembrane pore formation → rapid necrosis (poptosis)Pincus 2024 Krzesaj 2024

VIP → VPAC1/VPAC2 activation → cAMP elevation → Pulmonary vasodilation + epithelial protection

Downstream effect

Immediate cell lysis and extrusion of intracellular contents; secondary mitochondrial membrane disruptionPincus 2024 Krzesaj 2024

Anti-inflammatory cytokine modulation, alveolar-capillary membrane stabilization, pulmonary smooth muscle relaxation, reduced neutrophil infiltration

Feedback intact?

N/A — cytotoxic mechanism, not signaling modulation

Yes — exogenous VIP acts as physiological agonist

Origin

Chimeric design: p53 transactivating domain (12-26) fused to penetratin CPP sequenceSarafraz-Yazdi 2022

Endogenous 28-amino-acid neuropeptide; synthetic analogue (aviptadil) identical to natural VIP

Antibody development

—

02Dosage Protocols

Parameter

PNC-27

VIP

Clinical status

Pre-clinical only — no human trials

In vitro and animal model data only.

—

In vitro concentrations

10–100 μM range

Effective concentrations in cell culture studies.

—

Shorter analogue

PNC-28 (28 AA variant)

Retains HDM-2 binding and cytotoxic activity.

—

Evidence basis

Pre-clinical / In vitro

Phase 3 RCT (TESICO)Brown 2023

816-patient randomized controlled trial in COVID-19 ARDS.

Intravenous (ARDS protocol)

—

60–90 mcg/kg/day via continuous infusion

TESICO trial protocol for COVID-19 ARDS.

Infusion duration

—

12-hour continuous IV infusion dailyBrown 2023

Inhaled (investigational)

—

Variable dosing under clinical trial protocolsBoesing 2022

Delivered via nebulizer for direct pulmonary deposition.

Treatment duration

—

3–14 days (acute ARDS)

Reconstitution

—

Lyophilized powder reconstituted with sterile diluent per protocol

Half-life

—

~2 minutes (plasma)

Rapid clearance necessitates continuous infusion.

03Metabolic / Fat Loss Evidence

Parameter

PNC-27

VIP

Fat loss mechanism

None — cytotoxic anticancer agent

—

04Side Effects & Safety

Parameter

PNC-27

VIP

Human safety data

None available — no human trials conducted

—

Normal cell selectivity

In vitro: no cytotoxicity to normal cells (MCF-10-2A, peripheral blood mononuclear cells)Sarafraz-Yazdi 2010 Thadi 2020

Normal cells express minimal membrane HDM-2.

—

Cancer cell specificity

Depends on membrane HDM-2 expression levels

Ovarian cancer lines with low membrane HDM-2 showed <30% necrosis.

—

Cell death mechanism

Necrosis (not apoptosis) — rapid membrane lysisPincus 2024

—

Mitochondrial effects

Secondary mitochondrial membrane disruption in cancer cells

—

Hypotension

—

Transient vasodilation-related blood pressure drop

Tachycardia

—

Reflex tachycardia secondary to vasodilation

Infusion site reactions

—

Erythema, phlebitis (IV administration)

GI symptoms

—

Nausea, diarrhea (VIP is endogenous GI peptide)

Overall tolerability

—

Well-tolerated in Phase 3 trials; adverse event profile comparable to placebo

Absolute Contraindications

PNC-27

·Human use — no clinical trials or safety data

VIP

·Known hypersensitivity to aviptadil or formulation components

Relative Contraindications

PNC-27

—

VIP

·Severe hypotension or shock states (monitor blood pressure)
·Pregnancy — insufficient safety data

05Administration Protocol

Parameter

PNC-27

VIP

1. Pre-clinical status

PNC-27 has not been tested in human subjects. All data derive from in vitro cancer cell line studies and limited animal models. No approved clinical formulation, dosing protocol, or safety profile exists.Pincus 2024

Reconstitute lyophilized aviptadil powder with sterile diluent per manufacturer protocol. Inspect solution for particulates — should be clear and colorless.

2. Cell culture protocols

In vitro studies used 10–100 μM PNC-27 dissolved in cell culture medium. Peptide was added directly to cancer cell cultures (pancreatic, breast, colon, ovarian, leukemia lines) and incubated for 24–72 hours.

Administer as continuous 12-hour intravenous infusion via central or peripheral line. Use infusion pump for precise dosing (60–90 mcg/kg/day divided over infusion duration).

3. Fluorescent labeling studies

Dual-labeled PNC-27 (green on N-terminus, red on C-terminus) demonstrated intact peptide binding to cancer cell membranes with combined yellow fluorescence at 30 minutes, persisting during cell lysis.Sookraj 2010

Monitor blood pressure, heart rate, and oxygenation continuously during first infusion. Assess for hypotension and adjust infusion rate if needed.

4. Membrane HDM-2 requirement

Cytotoxicity correlates directly with membrane HDM-2 expression levels. Blocking HDM-2's p53-binding domain (1-109) with monoclonal antibodies prevents PNC-27-induced necrosis.

Deliver via jet or mesh nebulizer per clinical trial protocol. Patient seated upright, normal tidal breathing for 10–15 minutes.

5. Storage

—

Store lyophilized powder at 2–8 °C, light-protected. Reconstituted solution: use immediately or within 24 hours if refrigerated.